{
    "clinical_study": {
        "@rank": "30101", 
        "acronym": "Prodige20", 
        "arm_group": [
            {
                "arm_group_label": "chimiotherapy alone", 
                "arm_group_type": "Active Comparator", 
                "description": "LV5FU2 simplified,\n5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,\nfluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
            }, 
            {
                "arm_group_label": "chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks", 
                "arm_group_type": "Experimental", 
                "description": "LV5FU2 simplified,\nFOLFOX 4 simplified,\nFOLFIRI modified.\nBevacizumab 5 mg/kg/ 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly\n      patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm\n      with a chemotherapy alone arm in the first-line treatment of MCRC in patients aged 75 years\n      and older.\n\n      This study is destined to continue as a phase III trial if both arms meet the selection\n      criteria to show or not the benefits of treatment with bevacizumab combined with\n      chemotherapy."
        }, 
        "brief_title": "Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)", 
        "condition": "Metastatic Colorectal Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 75 years or older\n\n          -  ECOG \u22642\n\n          -  histologically proven unresectable metastatic colorectal adenocarcinoma\n\n          -  Measurable lesion according to RECIST criteria\n\n          -  Absence of prior chemotherapy for metastatic disease. Adjuvant chemotherapy following\n             resection of the primary tumor is authorized if completed more than 6 months\n             previously\n\n          -  Patients treated with anticoagulants (coumadin, warfarin) can be included if close\n             surveillance of the INR can be ensured. A change to low-molecular-weight heparin is\n             preferable as long as the indications are respected\n\n          -  Completed geriatric self\u2010questionnaire\n\n          -  Completed \"Team\" geriatric questionnaire (including Spitzer QoL Index)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Estimated life expectancy < 3 months\n\n          -  Non-resolved intestinal occlusion or sub\u2010occlusion\n\n          -  Cerebral metastasis\n\n          -  Other evolutive malignant tumor (non-stabilized cancer for less than 2 years)\n\n          -  Evolutive gastroduodenal ulcer, wound or bone fracture\n\n          -  Active heart disease: uncontrolled hypertension, myocardial infarction In the\n             previous 6 months, angina, non-compensated congestive heart failure\n\n          -  Major surgery, except for biopsy, or irradiation in the 4 weeks preceding the start\n             of treatment\n\n          -  Polynuclear neutrophils <1500/mm3, platelets <100 000/mm3 or 24-h proteinuria  > 1g\n\n          -  History of arterial thromboembolic event (cerebrovascular accident, transient\n             ischemic attack, subarachnoid hemorrhage) in the 12 months preceding the first dose\n             of bevacizumab\n\n          -  History of distal or visceral ischemia \u2265 grade 2 in the 12 months preceding the first\n             dose of bevacizumab\n\n          -  History of life-threatening pulmonary embolism in the 6 months preceding the first\n             dose of bevacizumab\n\n          -  Impossibility to ensure regular follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "75 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900717", 
            "org_study_id": "Bedenne PHRC K 2010.", 
            "secondary_id": "2010-022080-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "chimiotherapy alone", 
                "intervention_name": "LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks", 
                "intervention_name": "LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dijon", 
                    "country": "France", 
                    "zip": "21079"
                }, 
                "name": "CHU de Dijon"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "thoraco-abdomino-pelvic tomodensitometry or thoracic tomodensitometry and abdomino-pelvic MRI with identification and measurement of the target tumors according to RECIST (Response Evaluation Criteria in Solid Tumors\n)criteria.", 
            "measure": "Initial examination", 
            "safety_issue": "No", 
            "time_frame": "21 days before the first course of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Medical history, clinical examination (HR, arterial blood pressure\n, temperature, weight, height, Eastern Cooperative Oncology Group performance status),\nmeasurement of body surface area, ECG\ncompletion of questionnaire by the patient (annexe 1),\ncompletion of geriatric questionnaire \"team\" (annexe 2)\nbiological examination including:\nfull blood count-platelets\nblood electrolyte panel, creatinemia\nAlbumin\nASAT, ALAT, PAL, GGT, total and conjugated bilirubin\nCEA, CA 19.9, LDH markers\nbalanced INR for patients on AVK\nUrinary dip with 24-hour proteinuria if > 1+\nMeasurement of  creatinine clearance using the Cockcroft formula (in men: (140-age) x weight (kg)/0.814 x creatinemia (\u03bcmol), in women: (140-age) x weight (kg)/0.85 x creatinemia (\u03bcmol)),\nIn the absence of a cardiological examination in the year before or in the case of a history of severe cardiovascular disease: consultation in cardiology.", 
            "measure": "Initial examination", 
            "safety_issue": "No", 
            "time_frame": "14 days before inclusion"
        }, 
        "source": "Centre Hospitalier Universitaire Dijon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Dijon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}